This is a preview of subscription content, log in via an institution to check access.
References
de Jong M, Kwekkeboom D, Valkema R, et al. Radiola-beled peptides for tumor therapy: current status and fu-ture directions. Eur J Nucl Med Mol Imaging 2003;30:463–469.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Over-view of results of peptide receptor radionuclide therapy with 3 radiolabled somatostatin analogs. J Nucl Med 2005;46:62–66.
Paganelli G, Zoboli S, Cremonesi M, et al. Receptor medi-ated radionuclide therapy with 90Y-DOTA-D-Phe1-try3-octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 1999;14:477–483.
Bushnell D, O’Dorisio T, Menda T, et al. Evaluating the clinical effectiveness of 90 Y-SMT-487 in patients with neuro-endocrine tumors. J Nucl Med 2003;44:1556–1560.
Tuenissen JJM, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with 177 Lu-DOTA-octreotate. J Clin Oncol 2004;22:2724–2729.
Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 Gbq 90 Y-DOTATOC. J Nucl Med 2002;43:610–616.
McCarthy KE, Powers A, Lemen L, et al. Dosimetry of 111 In-pentetreotide predicts response to high dose radiother-apy with somatostatin analogs in patients with gastropancre-atic tumors. J Nucl Med 2002;43:34P.
de Jong M, Breeman WAP, Valkema R, et al. Combination radionuclide therapy using 177 Lu and 90 Y labeled somato-statin analogs. J Nucl Med 2005;46(s):13–17.
de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617–625.
Jamar F, Barone R, Mathieu I, et al. 86 Y-DOTA-D-Phe 1 -Try 3 -octreotide (SMT487)—a phase 1 clinical study: phar-macokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–518.
Bushnell D, Menda Y, O’Dorisio T, et al. Effects of intrave-nous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487 (OctreoTher ™)) treatment. Cancer Biother Radiopharm 2004;19:35–45.
Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9–15.
Valkema R, Pauwels S, Kvols L, et al. Long term follow-up of renal function after peptide receptor radiation therapy with 90 Y DOTA-try3-octreotide and 177 Lu DOTA-try3-octreotate. J Nucl Med 2005;46:83–91.
Barone R, Boroson-Chazot F, Valkema R, et al. Patient specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99–106.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bushnell, D. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. J Gastrointest Surg 10, 335–336 (2006). https://doi.org/10.1016/j.gassur.2005.08.025
Issue Date:
DOI: https://doi.org/10.1016/j.gassur.2005.08.025